Results for Maintenance Olaparib in BRCA-Mutated Platinum-Sensitive Ovarian Cancer

Early palliative care reduces invasive interventions and enhances comfort at EOL for CRC patients, according to real-world study results.

In season 2, episode 6 of Targeted Talks, Alexander B. Olawaiye, MD leads a discussion with Haider S. Mahdi, MD, about the modern approaches to treating cervical and endometrial cancers.

Adagrasib plus cetuximab sustained clinical efficacy in KRAS G12C–mutant unresectable or metastatic colorectal cancer with longer follow-up, according to the KRYSTAL-1 trial.

Sarah M. Temkin, MD leads discussion with Daphne B. Stewart, MD, around targeted therapies in ovarian cancer, whether offered in the academic or community setting.

Palliative care consultations in esophageal cancer improved QOL and reduced financial burden, according to ASCO GI poster findings.

Encorafenib, cetuximab, and mFOLFOX6 improved ORR over mFOLFOX6 alone in BRAF V600E-mutant mCRC in the BREAKWATER trial.